A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

September 27, 2020

Primary Completion Date

January 25, 2028

Study Completion Date

February 25, 2028

Conditions
Solid Tumors
Interventions
DRUG

ICP-723

ICP-723 is a white, round, uncoated table

Trial Locations (24)

100081

RECRUITING

Peking University Cancer Hospital, Beijing

RECRUITING

The First Medical Center of the Chinese People's Liberation Army General Hospital, Beijing

150000

RECRUITING

Cancer Hospital Affiliated to Harbin Medical University, Harbin

210000

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

214000

RECRUITING

Affiliated Hospital of Jiangnan University, Wuxi

230000

RECRUITING

The Second Affiliated Hospital of Anhui Medical University, Hefei

266000

RECRUITING

Affiliated Hospital of Qingdao University, Qingdao

310003

RECRUITING

The first affiliated hospital Zhejiang university school of medicine, Hangzhou

330000

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

410000

RECRUITING

Hunan Cancer hospital, Changsha

430000

RECRUITING

Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

471000

RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

510000

RECRUITING

Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangdong

519000

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

650000

RECRUITING

Yunnan Cancer Hospital, Kunming

050000

RECRUITING

Shijiazhuang People's Hospital, Shijiazhuang

Unknown

RECRUITING

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

030000

RECRUITING

Shanxi Cancer Hospital, Taiyuan

,310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT04685226 - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | Biotech Hunter | Biotech Hunter